Your SlideShare is downloading. ×
Leveraging Biometrics and Niche Global Expertise to Mitigate Risk, and Increase the Efficiency of Clinical Development    	  Suleman Verjee, Ph.D., President and CEO, Versante International, LLC
Leveraging Biometrics and Niche Global Expertise to Mitigate Risk, and Increase the Efficiency of Clinical Development    	  Suleman Verjee, Ph.D., President and CEO, Versante International, LLC
Leveraging Biometrics and Niche Global Expertise to Mitigate Risk, and Increase the Efficiency of Clinical Development    	  Suleman Verjee, Ph.D., President and CEO, Versante International, LLC
Leveraging Biometrics and Niche Global Expertise to Mitigate Risk, and Increase the Efficiency of Clinical Development    	  Suleman Verjee, Ph.D., President and CEO, Versante International, LLC
Leveraging Biometrics and Niche Global Expertise to Mitigate Risk, and Increase the Efficiency of Clinical Development    	  Suleman Verjee, Ph.D., President and CEO, Versante International, LLC
Leveraging Biometrics and Niche Global Expertise to Mitigate Risk, and Increase the Efficiency of Clinical Development    	  Suleman Verjee, Ph.D., President and CEO, Versante International, LLC
Leveraging Biometrics and Niche Global Expertise to Mitigate Risk, and Increase the Efficiency of Clinical Development    	  Suleman Verjee, Ph.D., President and CEO, Versante International, LLC
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Leveraging Biometrics and Niche Global Expertise to Mitigate Risk, and Increase the Efficiency of Clinical Development Suleman Verjee, Ph.D., President and CEO, Versante International, LLC

365

Published on

3rd Annual Challenges in Global Clinical Trials Conference, Jan. 28-29, 2010, San Diego, CA.

3rd Annual Challenges in Global Clinical Trials Conference, Jan. 28-29, 2010, San Diego, CA.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
365
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. CHALLENGES IN GLOBAL ` CLINICAL DEVELOPMENT Presented January 28, 2010 ENSURING ALL GOOD DRUGS ARE EFFECTIVELY TAKEN TO MARKET ENSURING ALL GOOD DRUGS ARE EFFECTIVELY TAKEN TO MARKET
  • 2. Meeting Agenda – Tough times demand good decision making and efficient clinical development – Leveraging biometrics to optimize clinical development • EDC systems and risk mitigation • Overcoming Current Medical Practice Challenges by Leveraging Statistics • Experience can salvage a clinical program jeopardized by poor planning – Strategic Paradigm for Global Clinical Development by Emerging and Mid-Size Companies ENSURING ALL GOOD DRUGS ARE EFFECTIVELY TAKEN TO MARKET
  • 3. • Case Studies TOUGH TIMES DEMAND GOOD DECISION MAKING AND EFFICIENT CLINICAL DEVELOPMENT ENSURING ALL GOOD DRUGS ARE EFFECTIVELY TAKEN TO MARKET ENSURING ALL GOOD DRUGS ARE EFFECTIVELY TAKEN TO MARKET
  • 4. Tough Times > Smart Development – Decrease in Venture Capital investment “Venture – Patent expirations and potential loss of revenues Capital investment – Shorter development cycles are critical and fundraising – Strategic solutions to study challenges slowed – Successful study results considerably in 2009 and – Identify and harness market potential, capture the interest of Large Pharma and Venture Capital will continue in 2010.” – Respond to higher demands in risk management NVCA ENSURING ALL GOOD DRUGS ARE EFFECTIVELY TAKEN TO MARKET
  • 5. • Case Studies LEVERAGING BIOMETRICS TO OPTIMIZE CLINICAL DEVELOPMENT ENSURING ALL GOOD DRUGS ARE EFFECTIVELY TAKEN TO MARKET ENSURING ALL GOOD DRUGS ARE EFFECTIVELY TAKEN TO MARKET
  • 6. EDC Systems and Risk Mitigation • EDC is generally seen as a tool which: – Collects data in ‘real time’ – Provides cleaner data – Enables faster database locking – More expensive option compared to paper • Paper-based systems are problematic due to: – Meeting eligibility criteria ensure uniformity of subjects across study sites – Paper based systems cannot ensure that criteria have been met – Paper based systems allow for more protocol deviations – Allow for shipment of drug – IVRS or not – if entry criteria not met – Violation of an entry criterion could lead to unnecessary safety concerns ENSURING ALL GOOD DRUGS ARE EFFECTIVELY TAKEN TO MARKET
  • 7. ATTENTION! The entire presentation is available to registered attendees only! To view the rest of this exciting presentation and many more! Please Register for the 3rd Annual Challenges in Global Clinical Trials Conference at www.gtcbio.com If you are already registered, please contact GTCbio for the full version.

×